MALE BLADDER CANCER DEATHS/10^3PY



GK GROUPING MBCD/10^3PY



EPA GROUPING MBCD/10^3PY



GK v EPA MBCD GROUPINGS



FEMALE BLADDER CANCER DEATHS/10^3PY



GK GROUPING FBCD/10^3PY



EPA GROUPING FBCD/10^3PY



GK v EPA FBCD GROUPINGS



GK LUNG+LIVER+BLADDER CANCER DEATHS/10^3PY



EPA LUNG+LIVER+BLAD. CANCER DEATHS/10^3PY



GK v EPA: L+L+B MCD/10^3PY



GK LUNG+LIVER+BLADDER CANCER DEATHS/10^3PY



EPA LUNG+LIVER+BLAD. CANCER DEATHS/10^3PY



GK v EPA: L+L+B FCD/10^3PY



CANCER MORTALITY IN UTAH MEN AND WOMEN



CANCER BENEFIT AT 50 PPB

- IF US POP. =285M, AND WOMEN = 50.5%, THEN:
- IF CURRENT CANCERS REFLECT As @ 50 PPB, THEN =>10 PPB = <u>INCREASE</u> OF 2,979 C/DAY, INCL. 1,301 CD/DAY
- IF CURRENT CANCERS REFLECT As @ 10 PPB, THEN =>50 PPB = <u>DECREASE</u> OF 1,024 C/DAY, INCL. 447 CD/DAY

HEART DISEASE MORTALITY IN UTAH



HEART DISEASE MORTALITY IN UTAH



HEART DISEASE BENEFIT AT 50 PPB

- IF US POP. =285M, AND MEN = 49.5%, THEN:
- IF CURRENT HEART DISEASE MORT. REFLECT As @ 50 PPB, THEN =>10 PPB = <u>INCREASE</u> OF 288 HDD/DAY
- IF CURRENT HEART DISEASE MORT. REFLECT As @ 10 PPB, THEN =>50 PPB = <u>DECREASE</u> OF 215 HHD/DAY

MOST RELIABLE DATA

- Rely on Significant
- Total [Cancer]
- in Men and Women
- REAL, i.e., not in need of extrapolation

REMEDIES

- Find arsenic around 50 µg/L to be a potent anticarcinogen compared to around 10 µg/L
- Reject contrary claims generated from lesser data
- Reject the cancer findings of the previous USEPA review of arsenic, used to justify lowering the arsenic standard to 10 µg/L

ARSENIC IN DRINKING WATER

GARY KAYAJANIAN, PH.D, J.D.

561/649-6629